Last reviewed · How we verify
IPG11406
At a glance
| Generic name | IPG11406 |
|---|---|
| Also known as | IPG11406 Placebo |
| Sponsor | Nanjing Immunophage Biotech Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase IIa Study for IPG11406 in Patients With Lupus Nephritis (PHASE1, PHASE2)
- Phase 1 Study for IPG11406 in Health Volunteer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPG11406 CI brief — competitive landscape report
- IPG11406 updates RSS · CI watch RSS
- Nanjing Immunophage Biotech Co., Ltd portfolio CI